source
- CRISPR Therapeutics to test highest dose of lipid‑lowering gene editing therapy after mixed durability dataCRISPR Therapeutics presented early‑stage data at the European Society of Cardiology meeting showing that its lipid‑lowering gene editing candidate produced mixed durability results a year after pa…
- Cardio firms including AstraZeneca and Novartis to showcase heart drug data at ESC 2026At the European Society of Cardiology's annual meeting in 2026, several pharmaceutical companies will present cardiovascular data. The lineup includes AstraZeneca, Ionis, Cytokinetics, Novartis an…